Inflammatory response is activated in end stage HF: a potential new therapeutic target?
Patients’ own immune response may have the potential to prevent the development and progression of heart failure (HF), according to research presented at Frontiers in CardioVascular Biology (FCVB) 2018, a European Society of Cardiology congress. The study found antibodies in the plasma and heart muscle of end-stage HF patients.
“The role of the immune response in the development of heart failure is unknown,” said Patricia van den Hoogen, a PhD student at the University Medical Centre Utrecht / Netherlands Heart Institute in Utrecht, the Netherlands. “We investigated the immune response in patients with end-stage heart failure to see if this might be a new target for treatment.”
The study looked at whether patients with end-stage HF show signs of inflammation. After a heart attack, inflammation processes clears dead cells and other resulting debris. Heart attacks damage the heart muscle and may eventually lead to HF, which is a progressive disease. For patients with end-stage HF, heart transplantation may be the only treatment option.
The study included 20 patients with end-stage HF and three healthy controls. HF was caused by ischemic heart disease in ten patients and by dilated cardiomyopathy in ten patients. The researchers analyzed heart tissue and plasma samples to see which antibodies and other immune cells were present. Next they tested the samples with different epitopes to see if they could find the targets of the antibodies.
The investigators found increased levels of antibodies in the heart and plasma of end-stage HF patients compared to healthy controls. Interestingly, antibody levels were higher in patients with ischemic HF compared to those with dilated HF. Levels of other types of immune cells, including T cells, B cells, and macrophages, were significantly higher in the heart tissue of HF patients compared to healthy controls. In the plasma, HF patients had different types of B cells than healthy controls. Specifically, HF patients had more plasma B cells, which produce antibodies, and fewer regulatory B cells, which are immunosuppressive. The epitope screening to identify antibody targets is ongoing. Based on their initial results, the researchers have selected 200 epitopes for follow-up studies.
Ms Van den Hoogen said: “These results suggest that the inflammatory response is activated and might play an important role in heart failure. These patients were in the final stage of heart failure,” she added. “In future studies we will investigate whether there is an inflammatory response in the early phase of heart failure, and whether the response becomes more pronounced as heart failure worsens.”
She concluded: “We now know there is an inflammatory response in patients with end-stage heart failure. This paves the way for creating new therapies to prevent the development or progression of heart failure by targeting the immune response. If we identify the targets of the antibodies through our epitope screening, personalized treatments could be designed.”
Source: Press release ESC, April 22 2018